<DOC>
	<DOCNO>NCT01507402</DOCNO>
	<brief_summary>This randomize , double-blind , placebo-controlled , single ascend dose study assess safety tolerability Intravenous ( IV ) Subcutaneous ( SC ) REGN1033 ( SAR391786 ) healthy volunteer .</brief_summary>
	<brief_title>A Study Assess Safety Tolerability Single Ascending Doses REGN1033 ( SAR391786 )</brief_title>
	<detailed_description />
	<criteria>1 . Healthy male postmenopausal surgically sterile female 2 . Body mass index ( BMI ) 18 30 kg/m2 inclusive 3 . Willing able return clinic visit complete studyrelated procedure 4 . Able read understand , willing sign ICF 1 . Significant concomitant illness history significant illness , limited cardiac , renal , rheumatologic , neurologic , psychiatric , endocrine , metabolic lymphatic disease would adversely affect subject 's participation study 2 . History muscle neoplasm rhabdomyoma , rhabdomyosarcoma , leiomyoma , leiomyosarcoma uterine fibroid tumor 3 . History muscular dystrophy , myositis , primary disease skeletal muscle 4 . History heart diseases include limited coronary heart disease with/without history myocardial infarction , chronic acute heart failure , cardiac arrhythmia , valvular heart disease cardiac hypertrophy . Subjects take prophylactic aspirin exclude study discontinue take prophylactic aspirin participate study 5 . History systemic hypertension use concomitant medication treat hypertension , history pulmonary hypertension 6 . History diabetes mellitus gestational diabetes use concomitant medication treatment 7 . Recent use androgenic steroid 8 . Unexplained creatine phosphokinase ( CPK ) level &gt; 3X upper limit normal . 9 . Any medical psychiatric condition , opinion investigator , would place subject risk , interfere participation study interfere interpretation study result 10 . Women childbearing potential ( surgically sterile amenorrheic least twelve month postmenopausal ) 11 . Onset new exercise routine major change previous exercise diet routine within 4 week prior screen . Subjects must willing maintain his/her previous level exercise duration study 12 . Known history seropositivity human immunodeficiency virus ( HIV ) antibody ; hepatitis B surface antigen hepatitis C antibody ( HCV ) associate positive HCV RNA polymerase chain reaction screen visit 13 . Positive urine drug test result screen history drug alcohol abuse within year prior screen visit 14 . Any hospitalization within 60 day prior screen visit 15 . Participation clinical research study evaluate another investigational drug therapy within 30 day least 5 halflives , whichever longer , investigational drug , prior screen visit 16 . History hypersensitivity reaction doxycycline tetracycline drug 17 . Previous exposure biological therapeutic agent , except vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>